A surprising discovery reveals how a single protein helps cells decide when to make the building blocks of DNA. Researchers at CeMM, together with collaborators from the University of Oxford, have discovered that the enzyme NUDT5 acts not through its chemical activity, but as a physical “scaffold” that helps switch off a key metabolic pathway when purine levels are high. The study, published in Science (DOI 10.1126/science.adv4257), reveals a mechanism with implications for cancer treatment and inherited metabolic disorders.

Spatial maps of lung precancer and cancer cells at different points in development advance understanding of the earliest stages of lung cancer

Findings highlight inflammation as a driver of lung tumor initiation

Targeting inflammation could be a potential therapeutic strategy to intercept lung cancer and improve patient outcomes

A cellular resistance mechanism at the origin of relapses of triple-negative breast cancer has recently been discovered by scientists from CNRS, Institut Curie and Université Paris Cité. Their findings have been published in Cancer Research, a journal of the American Association for Cancer Research, on 6 November 2025.

Metastasis remains the deadliest cancer complication, driven by circulating tumor cells (CTCs) that evade immune defenses in the bloodstream. A new review by scientists of China explores how CTCs interact with platelets, immune cells, and molecular pathways to survive, highlighting emerging therapeutic strategies and the evolving role of CTCs in liquid biopsy and metastasis prevention. The findings offer promising directions for advancing cancer diagnostics and anti-metastatic treatments.